159 related articles for article (PubMed ID: 37531116)
1. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
3. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
4. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
8. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
Hu L; Huang R; Jiang F; You S; Wu Q
Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
[TBL] [Abstract][Full Text] [Related]
9. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results.
Kamata A; Kurihara Y; Funakoshi T; Takahashi H; Kuroda K; Hachiya T; Amagai M; Yamagami J
Br J Dermatol; 2020 May; 182(5):1221-1227. PubMed ID: 31330562
[TBL] [Abstract][Full Text] [Related]
10. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid.
Masmoudi W; Vaillant M; Vassileva S; Patsatsi A; Quereux G; Moltrasio C; Abasq C; Prost-Squarcioni C; Kottler D; Kiritsi D; Litrowski N; Plantin P; Friedrichsen L; Zebrowska A; Duvert-Lehembre S; Hofmann S; Ferranti V; Jouen F; Joly P; Hebert V;
Br J Dermatol; 2021 Jun; 184(6):1106-1112. PubMed ID: 33067805
[TBL] [Abstract][Full Text] [Related]
11. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.
Yan T; Xie Y; Liu Y; Shan Y; Wu X; Wang J; Zuo YG; Zhang Z
Front Immunol; 2023; 14():1194088. PubMed ID: 37575240
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Chebani R; Lombart F; Chaby G; Dadban A; Debarbieux S; Viguier MA; Ingen-Housz-Oro S; Pham-Ledard A; Bedane CR; Picard-Dahan C; Berthin C; Dereure O; Konstantinou MP; Castel M; Jouen F; Joly P; Seta V; Duvert-Lehembre S; Le Roux C; Quereux G; Sassolas B; Brenaut E; Sin C; Richard MA; Bérard F; Giusti D; Belmondo T; Gille T; Caux F; Prost-Squarcioni C; Grootenboer-Mignot S; Alexandre M;
Br J Dermatol; 2024 Jan; 190(2):258-265. PubMed ID: 37792727
[TBL] [Abstract][Full Text] [Related]
14. Circulating bullous pemphigoid autoantibodies in the setting of negative direct immunofluorescence findings for bullous pemphigoid: A single-center retrospective review.
Wang M; Lehman JS; Camilleri MJ; Drage LA; Wieland CN
J Am Acad Dermatol; 2019 Aug; 81(2):472-479. PubMed ID: 30928465
[TBL] [Abstract][Full Text] [Related]
15. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
16. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.
Patsatsi A; Kyriakou A; Pavlitou-Tsiontsi A; Giannakou A; Sotiriadis D
Clin Dev Immunol; 2012; 2012():854795. PubMed ID: 23227089
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
18. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
Wang SH; Shan Y; Li SZ; Zuo YG
Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
[TBL] [Abstract][Full Text] [Related]
19. Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study.
Chanprapaph K; Ounsakul V; Pruettivorawongse D; Thadanipon K
Asian Pac J Allergy Immunol; 2021 Dec; 39(4):272-278. PubMed ID: 31175713
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
